Dintenfass, L.
July 1973
Angiology;Jul/Aug1973, Vol. 24 Issue 7, p422
Academic Journal
The aim of this paper is to present an evidence that ABO blood-groups play a key role in the rheology of blood in cardiovascular diseases, that they might influence the pathways of aetiology of those diseases, especially in relation to the microcirculation, tissue perfusion and thrombus formation, and that there exists a possibility that ABO blood-group specific drugs might be more effective in counteracting a development and progress of these diseases than drugs which do not take any account of inherent differences between patients of different ABO blood groups.


Related Articles

  • Key learning points.  // Pulse;11/9/2011, Vol. 71 Issue 37, p32 

    The article offers information on various topics related to renal medicine including the need for people with chronic kidney disease (CKD) to undergo blood tests at least every six months, hyponatraemia was the result of secondary hyperaldosteronism, and cardiovascular disease causes the death...

  • Metabolic Disorders in Patients with Chronic Kidney Failure. Cibulka, R.; Racek, J. // Physiological Research;2007, Vol. 56 Issue 6, p697 

    This review article summarizes the problems of metabolic disorders and nutrition imbalances that often occur in chronic kidney failure (CKF) or following regular dialysis treatment. In this survey, we cover the pathogenesis of these disorders, their clinical consequences, and their association...

  • Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines. Klaus, G.; Watson, A.; Edefonti, A.; Fischbach, M.; Rönnholm, K.; Schaefer, F.; Simkova, E.; Stefanidis, C.; Strazdins, V.; Walle, J.; Schröder, C.; Zurowska, A.; Ekim, M. // Pediatric Nephrology;Feb2006, Vol. 21 Issue 2, p151 

    Childhood renal osteodystrophy (ROD) is the consequence of disturbances of the calcium-regulating hormones vitamin D and parathyroid hormone (PTH) as well as of the somatotroph hormone axis associated with local modulation of bone and growth cartilage function. The resulting growth retardation...

  • Long Interdialytic Interval and Mortality among Patients Receiving Hemodialysis. Foley, Robert N.; Murray, Thomas; Collins, Allan J.; Gilbertson, David T. // New England Journal of Medicine;9/22/2011, Vol. 365 Issue 12, p1099 

    Background: Patients with end-stage renal disease requiring dialysis have limited tolerance of metabolic and volume-related deviations from normal ranges; in addition, the prevalence of cardiovascular disease is high among such patients. Given these problems, we hypothesized that a long...

  • Little evidence for antiplatelets in CKD.  // Pulse;3/21/2012, Vol. 72 Issue 10, p12 

    The article focuses on the meta-analysis published in the "Annals of Internal Medicine," which shows less evidence on the use of antiplatelets for primary and secondary prevention of cardiovascular cases in patients with chronic kidney disease (CKD).

  • COMPLICAÅ¢IILE INFECÅ¢IOASE LA PACIENÅ¢II VÂRSTNICI CU BOALÄ‚ CRONICÄ‚ DE RINICHI. Văcăroiu, Ileana; David, Cristiana; Rădulescu, Daniela; Ciocâlteu, Alexandru; Checheriţă, Ionel Alexandru // Romanian Journal of Infectious Diseases;2011, Vol. 14 Issue 2, p85 

    Incidence of chronic kidney disease have considerably increased in the last decade mainly in the elderly age groups. Infectious complications, the second cause of mortality in uremics after cardiovascular diseases, are more severe in elderly as a result of a complex interaction between immune...

  • The re-emergence of short daily haemodialysis. Schiller, Brigitte // Nephrology Dialysis Transplantation;Dec2011 Supplement 3, Vol. 4 Issue suppl_3, piii29 

    Thrice weekly in-center hemodialysis is the standard of care for dialysis patients with end-stage renal disease (ESRD). However, there is ongoing debate as to whether more frequent hemodialysis, with its readier management of both toxin and fluid removal, benefits patients. New evidence from...

  • NP Program Improves CKD Cardiac Risk Factors.  // Renal & Urology News;Oct2011, Vol. 10 Issue 10, p24 

    The article reports that the study conducted by Arjan van Zuilen of the University Medical Center Utrecht found that a polydrug and lifestyle treatment strategy with nurse practitioner (NP) support can improve the management of some cardiovascular (CV) risk factors in chronic kidney disease (CKD).

  • Understanding the effects of chronic kidney disease on cardiovascular risk: are there lessons to be learnt from healthy kidney donors? Moody, W E; Chue, C D; Inston, N G; Edwards, N C; Steeds, R P; Ferro, C J; Townend, J N // Journal of Human Hypertension;Mar2012, Vol. 26 Issue 3, p141 

    Chronic kidney disease (CKD) is now a recognized global public health problem. It is highly prevalent and strongly associated with hypertension and cardiovascular disease (CVD); far more patients with a glomerular filtration rate below 60 ml min−1 per 1.73 m2 will die from cardiovascular...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics